Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease)

Simon Dulz; C Schwering; Jan Wildner; Christoph Spartalis; Frank Schuettauf; Udo Bartsch; Eva Wibbeler; Miriam Nickel; Martin Stephan Spitzer; Yevgeniya Atiskova; Angela Schulz

doi:10.1136/bjo-2022-321260

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via AAO

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Browse by collection

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via AAO

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF

Clinical science

Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Dulz S, Schwering C, Wildner J, et al

Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease)

British Journal of Ophthalmology 2023;107:1478-1483.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password